AFP and hepatocellular carcinoma: Moreover, high pre-treatment serum AFP-L3% exhibited strong association with OS in HCC patients treated by RFA and multiple treatment (HR: 1.50, 95% CI: 1.24–1.81, p<0.0001; HR: 1.97, 95% CI: 1.51–2.58, p<0.00001, respectively) without heterogeneity in the data (x2 = 0.49, I2 = 0%, p = 0.78; x2 = 1.52, I2 = 0%, p = 0.68, respectively).